Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
BMS Not Yet Recruiting Study icon

Not Yet Recruiting

Trial ID CA127-1070  |   NCT06352528

A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment

Warning icon
Sorry, this study is not yet accepting participants.
Please bookmark this page to check back at a later date.  You may also click the “Check Your Eligibility” button and answer a few questions about your health to find out if you might be a match to another study.

Summary

  • Phase 1
  • Male and Female Gender icon
  • 18-75
    Age Range
  • 3
    Locations
  • BMS Not Yet Recruiting Study icon
    Not Yet Recruiting

Overview

The purpose of this study is to assess the drug levels of a single oral dose of repotrectinib in participants with moderate and severe HI, and in healthy matched control participants with normal hepatic function.

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
:
  • Inclusion Criteria for all Participants (Group 1, Group 2, Group 3):.
    1. Adult female (as assigned at birth) not of childbearing potential or male (as assigned at birth) of any race or ethnicity.
      1. Must have a body mass index between 18 and 40 kg/m2 (inclusive) and body weight ≥ 50 kg at the time of signing the ICF.
      2. Inclusion Criteria for Participants with Moderate or Severe Hepatic Impairment (Group 1 and Group 2):.
        1. Participants have moderate or severe HI or cirrhosis due to chronic hepatic disease and/or prior alcohol use.
          1. Participants have moderate (Group 1), or severe (Group 2) HI as defined by Child-Pugh score.
          2. Inclusion Criteria for a Matched Healthy Participant (Group 3):.
            1. Participant must be free of any clinically significant disease that would interfere with the study evaluations.
              1. Participant must have liver-related laboratory test results within the respective reference ranges or with clinically insignificant excursions therefrom as agreed by the investigator.
                1. Participant must be in good health as determined by past medical history, physical examination, vital signs, ECG, and clinical laboratory safety tests. Clinical laboratory safety tests (eg, hematology, chemistry, and urinalysis) and 12-lead ECGs must be within normal limits or clinically acceptable as judged by the investigator.

                Exclusion Criteria

                Exclusion Criteria Icon
                :
                • Exclusion Criteria for all Participants (Group 1, Group 2, and Group 3):.
                  1. Any major surgery within 4 weeks of the study intervention administration.
                    1. History of drug abuse within 1 year of study intervention administration.
                      1. History of alcohol abuse within 1 year of study intervention administration.
                        1. Participants who currently smoke, as well as those who have stopped smoking less than 6 months prior to dosing on Day 1.
                        2. Other protocol-defined Inclusion/Exclusion criteria apply.
                          Additional Information *

                          Treatment Options

                          Study Arms

                          ASSIGNED INTERVENTION

                          Study Arms

                          Experimental: Group 1: Moderate Hepatic Impairment

                          ASSIGNED INTERVENTION
                          • Drug: Repotrectinib

                          Study Arms

                          Experimental: Group 2: Severe Hepatic Impairment

                          ASSIGNED INTERVENTION
                          • Drug: Repotrectinib

                          Study Arms

                          Experimental: Group 3: Normal Hepatic Function

                          ASSIGNED INTERVENTION
                          • Drug: Repotrectinib
                          Please check back later for a recruiting site or find another trial by clicking 'Check Your Eligibility'
                          Check Your Eligibility
                          Answer some questions about Your health to see if you may match to this trial
                          Match to a Trial
                          If you are a match, click on the study to see the list of study site locations.
                          Select a Study Site Location
                          Select a study site location that is convenient for you
                          Register
                          Provide your contact details for the study site to connect with you.

                          Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you